A Passion for Science and a Commitment to Dermatology

Dermavant Sciences is a specialty biopharmaceutical company developing innovative prescription therapies for dermatologic diseases. Dermavant has acquired promising compounds that address unmet therapeutic needs and has rapidly established a robust dermatology R&D pipeline. We are dedicated to realizing the full potential of biomedical research and to developing and commercializing novel first-in-class or best-in-class therapies that improve patients’ lives. The patient is at the heart of everything we do.

*Completion of transaction with GSK anticipated during the second half of 2018, subject to necessary approvals, anti‐trust, and regulatory clearances.
Investigational drugs. Have not been approved for any indication and subject to health authority approval.

Learn More

Latest News

July 12, 2018

Roivant subsidiary Dermavant Sciences signs agreem ...

Read More

June 19, 2018

Dermavant to Present at JMP Securities Life Scienc ...

Read More

April 3, 2018

Dermavant Expands Pipeline and Strengthens Executi ...

Read More